Does Colchicine Cause an Increase in Blood Glucose?
Colchicine does not cause clinically significant increases in blood glucose in most patients and may even have beneficial metabolic effects in certain populations, though older animal and human studies from the 1970s-1980s showed transient impairment of insulin secretion.
Evidence from Guidelines and Drug Labels
The FDA drug label for colchicine does not list hyperglycemia or elevated blood glucose as a recognized adverse effect 1. The major warnings focus on fatal overdose, blood dyscrasias, drug interactions, and neuromuscular toxicity—but glucose metabolism is notably absent 1.
Multiple high-quality guidelines addressing colchicine use (EULAR recommendations for gout and familial Mediterranean fever, ESC heart failure guidelines, ACR gout guidelines) make no mention of blood glucose monitoring or diabetes as a concern with colchicine therapy 2, 3, 4, 3, 5. The ESC guidelines specifically note that gout attacks in heart failure patients are "better treated by colchicine than with NSAIDs" without any caution regarding glucose effects 4.
Contemporary Research Evidence
Recent high-quality studies contradict the older concern and suggest potential metabolic benefits:
The LoDoCo2 trial (2023) in 5,522 patients with chronic coronary artery disease found that colchicine 0.5 mg daily actually showed a trend toward reducing new-onset type 2 diabetes: 1.5% incidence in the colchicine group versus 2.2% in placebo (p=0.10), though this did not reach statistical significance 6.
A 2019 randomized controlled trial in adults with metabolic syndrome (but without diabetes) found that colchicine 0.6 mg twice daily for 3 months showed improvements in HOMA-IR (p=0.0499) and fasting insulin (p=0.07), suggesting metabolic benefit rather than harm 7.
A 2025 randomized trial in 100 patients with type 2 diabetes found that colchicine 0.5 mg daily for 26 weeks had no adverse effects on glycemic control and was well-tolerated 8, 9.
A 1993 Indian study actually reported that colchicine 0.5 mg three times daily significantly reduced both fasting and post-prandial blood glucose in patients with type 2 diabetes, suggesting anti-diabetic properties 10.
Historical Context: The 1970s-1980s Studies
The concern about colchicine and glucose stems from older animal and human studies:
A 1981 study showed acute IV colchicine (3 mg) temporarily decreased insulin response to glucose in humans, which was completely reversed by lysine acetylsalicylate 11.
A 1978 rat study showed both acute and chronic colchicine impaired insulin secretion 12.
These findings have not been replicated in modern clinical trials and appear to represent a transient pharmacologic effect rather than a clinically relevant problem.
Clinical Recommendation
Colchicine can be safely used in patients with diabetes or at risk for diabetes without specific concern for worsening glycemic control. The weight of contemporary evidence, including large cardiovascular outcome trials and the absence of warnings in FDA labeling and major guidelines, supports that any theoretical effect on insulin secretion does not translate into clinically meaningful hyperglycemia.
Key Points:
- No routine blood glucose monitoring is required specifically for colchicine therapy
- Colchicine may actually have modest beneficial metabolic effects in some populations
- The drug remains appropriate for gout flares and prophylaxis in diabetic patients
- Standard diabetes monitoring should continue as clinically indicated, but not because of colchicine
Common Pitfall to Avoid:
Do not withhold colchicine from diabetic patients based on outdated concerns from 1970s-1980s studies. The contemporary evidence base, including trials specifically in diabetic populations, demonstrates safety and potential benefit.